Lineage Cell Therapeutics: Gains on plans to restart clinical testing of spinal cord therapy

Lineage Cell Therapeutics

22/06/2021 13:12

** Shares of cell therapy developer  LCTX.A  rise 2.2% to
$2.74 premarket
    ** Co says its therapy for treatment of spinal cord injury,
OPC1, will return to clinical testing  urn:newsml:reuters.com:*:nBwbmg53Ka
    ** Following FDA feedback, LCTX will submit amendment to its
clinical study application to support an early-stage study to
test a new delivery system for OPC1
    ** Neurgain PSD system has been designed to allow for
administration of treatment to spinal cord without stopping
patient's ventilator during the procedure - LCTX
    ** Amendment is expected to be submitted in Q4 of 2021
    ** Co expects to start late-stage study of spinal cord
injury program in 2022
    ** As of last close, LCTX had gained about 52% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))